← Leaderboards
Anne Davidson
Feinstein Institute For Medical Research
$18,272,977
Attributed
$19,662,231
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,675,015 · 22
By mechanism
R01$13,498,473 · 7
U19$8,034,187 · 5
R21$2,116,369 · 5
T32$1,432,706 · 1
R56$424,780 · 1
R03$168,500 · 1
Top collaborators
- Betty Diamond12 shared
- Marcus R Clark2 shared
- Joseph E Craft2 shared
Most similar at Feinstein Institute For Medical Research
Same institution · by research overlap
- Betty Diamond$68,537,262
- Meera Ramanujam$82,500
- Venkatesh Jeganathan$78,505
- Weiqing Huang$162,516
- Bruce Thomas Volpe$13,363,924
Others in their field
Top investigators on “Systemic Lupus Erythematosus”
- Ignacio E. Sanz · University Of Rochester$57,737,718
- George C Tsokos · Beth Israel Deaconess Medical Center$37,219,358
- David Wofsy · University Of California, San Francisco$36,472,228
- Betty Diamond · Feinstein Institute For Medical Research$32,406,714
- John Barker Harley · Cincinnati Va Medical Center Research$30,355,689
- Patrick M Gaffney · University Of Minnesota Twin Cities$27,964,103
Research focus
Systemic Lupus ErythematosusLupusCellsResponseCytokineAntibodiesB-LymphocytesInflammationInflammatoryMouse ModelProductionTissuesPlasma CellsPathway InteractionsMediatingT-LymphocyteAutoimmune DiseasesAutoantibodiesClinical TrialsNovel TherapeuticsAutoreactive B CellAutoimmunityMacrophageImmune
Grant awards (67)
Using artificial intelligence to bridge human and murine studies of lupus nephritis progression$801,945
R01 · FY2025 · AI
A mechanistic understanding of B cell and macrophage plasticity in lupus disease activity states$779,404
U19 · FY2025 · AI
Dissecting the heterogeneity and function of myeloid cells in lupus nephritis$592,335
R01 · FY2025 · DK · contact PI
T32 Training Grant in Translational Immunology$302,406
T32 · FY2025 · AI · contact PI
Collaborative Project-Predicting LN flare and activity by an analysis of blood and urine$251,250
U19 · FY2025 · AI · contact PI
A mechanistic understanding of B cell and macrophage plasticity in lupus disease activity states$794,260
U19 · FY2024 · AI
Using artificial intelligence to bridge human and murine studies of lupus nephritis progression$752,511
R01 · FY2024 · AI
Dissecting the heterogeneity and function of myeloid cells in lupus nephritis$628,286
R01 · FY2024 · DK · contact PI
T32 Training Grant in Translational Immunology$333,436
T32 · FY2024 · AI · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$639,114
U19 · FY2023 · AI
Dissecting the heterogeneity and function of myeloid cells in lupus nephritis$618,239
R01 · FY2023 · DK · contact PI
T32 Training Grant in Translational Immunology$276,908
T32 · FY2023 · AI · contact PI
Project-003$244,006
U19 · FY2023 · AI
T32 Training Grant in Translational Immunology$352,665
T32 · FY2022 · AI · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$316,209
U19 · FY2022 · AI
Mechanisms for Human TLR8 induced pregnancy loss in a mouse model of SLE$254,354
R21 · FY2022 · AI · contact PI
Project-003$221,981
U19 · FY2022 · AI
Induction of lupus-related autoantibodies by TNF inhibitors$684,079
U19 · FY2021 · AI · contact PI
Etiology and outcome of MIS-C (PRISM)$684,079
U19 · FY2021 · AI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$319,827
U19 · FY2021 · AI
Project-003$239,913
U19 · FY2021 · AI
Mechanisms for Human TLR8 induced pregnancy loss in a mouse model of SLE$229,354
R21 · FY2021 · AI · contact PI
Circadian dysregulation of immune function in SLE$226,529
R21 · FY2021 · AR · contact PI
T32 Training Grant in Translational Immunology$167,291
T32 · FY2021 · AI · contact PI
Etiology and outcome of MIS-C$1,491,907
U19 · FY2020 · AI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$446,734
U19 · FY2020 · AI
Circadian dysregulation of immune function in SLE$197,158
R21 · FY2020 · AR · contact PI
Induction of lupus-related autoantibodies by TNF inhibitors$125,625
U19 · FY2020 · AI · contact PI
Heterogeneous pathways to autoantibody production: implications for prognosis and therapeutic targeting$541,250
U19 · FY2019 · AI
Induction of lupus-related autoantibodies by TNF inhibitors$254,549
U19 · FY2019 · AI · contact PI
Mechanisms of therapeutic efficacy of BAFF inhibition using belimumab$440,538
R01 · FY2018 · AR · contact PI
Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis$217,800
R21 · FY2018 · AR · contact PI
Mechanisms of therapeutic efficacy of BAFF inhibition using belimumab$440,538
R01 · FY2017 · AR · contact PI
The role of TNF in B cell tolerance in SLE$222,420
R21 · FY2017 · AR · contact PI
Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis$181,500
R21 · FY2017 · AR · contact PI
Mechanisms of therapeutic efficacy of BAFF inhibition using belimumab$440,538
R01 · FY2016 · AR · contact PI
The role of TNF in B cell tolerance in SLE$185,350
R21 · FY2016 · AR · contact PI
Mechanisms of therapeutic efficacy of BAFF inhibition using belimumab$440,538
R01 · FY2015 · AR · contact PI
Novel models for defining function of the BAFF/APRIL cytokine family$84,250
R03 · FY2015 · AI · contact PI
Regulation of the anti-phospholipid response in SLE$490,330
R01 · FY2014 · AI · contact PI
Mechanisms of therapeutic efficacy of BAFF inhibition using belimumab$440,538
R01 · FY2014 · AR · contact PI
Novel models for defining function of the BAFF/APRIL cytokine family$84,250
R03 · FY2014 · AI · contact PI
Targeting renal inflammatory pathways of SLE nephritis in mouse and man$515,743
R01 · FY2013 · DK · contact PI
Regulation of the anti-phospholipid response in SLE$395,552
R01 · FY2013 · AI · contact PI
Regulation of the anti-phospholipid response in SLE$44,491
R01 · FY2013 · AI · contact PI
Targeting renal inflammatory pathways of SLE nephritis in mouse and man$534,824
R01 · FY2012 · DK · contact PI
Regulation of the anti-phospholipid response in SLE$420,800
R01 · FY2012 · AI · contact PI
Targeting renal inflammatory pathways of SLE nephritis in mouse and man$535,211
R01 · FY2011 · DK · contact PI
Regulation of the anti-phospholipid response in SLE$420,800
R01 · FY2011 · AI · contact PI
Functional significance of an ITGAM polymorphism in SLE$143,424
R21 · FY2011 · AR · contact PI
Targeting renal inflammatory pathways of SLE nephritis in mouse and man$649,579
R01 · FY2010 · DK · contact PI
Regulation of the anti-phospholipid response in SLE$424,925
R01 · FY2010 · AI · contact PI
Functional significance of an ITGAM polymorphism in SLE$258,480
R21 · FY2010 · AR · contact PI
Regulation of the anti-phospholipid response in SLE$424,780
R56 · FY2009 · AI · contact PI
Novel Costimulatory Antagonists for SLE$412,899
R01 · FY2009 · AR · contact PI
Novel Costimulatory Antagonists for SLE$400,952
R01 · FY2008 · AR · contact PI
Novel Costimulatory Antagonists for SLE$412,891
R01 · FY2007 · AR · contact PI
Novel Costimulatory Antagonists for SLE$402,910
R01 · FY2006 · AR · contact PI
Novel Costimulatory Antagonists for SLE$390,351
R01 · FY2005 · AR
MECHANISM OF ACTION OF CTLA41G &ANTI-CD40L IN MURINE$167,000
R01 · FY2004 · AI
MECHANISM OF ACTION OF CTLA41G &ANTI-CD40L IN MURINE$120,750
R01 · FY2004 · AI
MECHANISM OF ACTION OF CTLA41G &ANTI-CD40L IN MURINE$292,250
R01 · FY2003 · AI
MECHANISM OF ACTION OF CTLA41G &ANTI-CD40L IN MURINE$292,396
R01 · FY2002 · AI
Core--Protein Expression and Tetramer$0
P01 · FY2002 · AI
Costimulartory antagonists /systemic lupus erythematosus$0
P01 · FY2002 · AI
MECHANISM OF ACTION OF CTLA41G &ANTI-CD40L IN MURINE$293,125
R01 · FY2001 · AI
MECHANISM OF ACTION OF CTLA41G &ANTI-CD40L IN MURINE$284,688
R01 · FY2000 · AI